Michael Lattanzi

927 total citations
19 papers, 646 citations indexed

About

Michael Lattanzi is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Michael Lattanzi has authored 19 papers receiving a total of 646 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Michael Lattanzi's work include Bladder and Urothelial Cancer Treatments (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Urinary and Genital Oncology Studies (4 papers). Michael Lattanzi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Urinary and Genital Oncology Studies (4 papers). Michael Lattanzi collaborates with scholars based in United States, India and Argentina. Michael Lattanzi's co-authors include Jingguang G. Chen, Wanfeng Li, Qi Lu, Xiaoming Kou, Yunpeng Chen, K. M. Unruh, Xin Fan, John Q. Xiao, Jonathan E. Rosenberg and Anna C. Pavlick and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Michael Lattanzi

17 papers receiving 631 citations

Peers

Michael Lattanzi

EOMM

EEE

RESE

ONCOL

PP

Sipeng Guo China

Yongju Yoo South Korea

Liming Wang China

Sizhen Wang China

Xue Li Wang China

Chunyang Lu China

Shin‐Yeong Kim South Korea

Yuyun Sun China

Sun Ha Park South Korea

Sipeng Guo China

Michael Lattanzi

153 ×0.4

EOMM

117 ×0.3

EEE

69 ×0.5

RESE

156 ×1.1

ONCOL

47 ×0.4

PP

Citations per year, relative to Michael Lattanzi Michael Lattanzi (= 1×) peers Sipeng Guo

Countries citing papers authored by Michael Lattanzi

Since Specialization

Citations

This map shows the geographic impact of Michael Lattanzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lattanzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lattanzi more than expected).

Fields of papers citing papers by Michael Lattanzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lattanzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lattanzi. The network helps show where Michael Lattanzi may publish in the future.

Co-authorship network of co-authors of Michael Lattanzi

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lattanzi. A scholar is included among the top collaborators of Michael Lattanzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lattanzi. Michael Lattanzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Guercio, Brendan J., Michal Sarfaty, Min Yuen Teo, et al.. (2022). Abstract 3410: Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced/metastatic urothelial cancer (mUC). Cancer Research. 82(12_Supplement). 3410–3410. 1 indexed citations

2.

Lattanzi, Michael, Junting Zheng, Chelsea Nichols, et al.. (2022). Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).. Journal of Clinical Oncology. 40(6_suppl). 556–556. 7 indexed citations

3.

Lattanzi, Michael, Alexander Solovyov, Jayon Lihm, et al.. (2022). Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.. Journal of Clinical Oncology. 40(16_suppl). 4584–4584. 2 indexed citations

4.

Guercio, Brendan J., Jatin Gandhi, Min Yuen Teo, et al.. (2021). Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.. Journal of Clinical Oncology. 39(15_suppl). 4526–4526. 2 indexed citations

5.

Funt, Samuel A., Michael Lattanzi, Karissa Whiting, et al.. (2021). Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.. Journal of Clinical Oncology. 39(15_suppl). 4517–4517. 7 indexed citations

6.

Lattanzi, Michael & Jonathan E. Rosenberg. (2020). The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Review of Anticancer Therapy. 20(7). 551–561. 24 indexed citations

7.

Pavlick, Anna C., Ana-Belén Blázquez, Marcia Meseck, et al.. (2019). Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunology Research. 8(1). 70–80. 56 indexed citations

8.

Lattanzi, Michael & Arjun Vasant Balar. (2019). Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. Current Oncology Reports. 21(3). 24–24. 13 indexed citations

9.

Lattanzi, Michael, Fang‐Ming Deng, Luis Chiriboga, et al.. (2019). Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy.. Journal of Clinical Oncology. 37(15_suppl). e16018–e16018.

10.

Lattanzi, Michael, Fang‐Ming Deng, Luis Chiriboga, et al.. (2018). Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. Journal for ImmunoTherapy of Cancer. 6(1). 97–97. 22 indexed citations

11.

Lattanzi, Michael, Joseph K. Han, Una Moran, et al.. (2018). Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Journal for ImmunoTherapy of Cancer. 6(1). 38–38. 11 indexed citations

12.

Lattanzi, Michael, Yesung Lee, Danny Simpson, et al.. (2018). Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. JNCI Journal of the National Cancer Institute. 111(2). 180–188. 62 indexed citations

13.

Lattanzi, Michael, Yesung Lee, Eric M. Robinson, et al.. (2017). Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.. Journal of Clinical Oncology. 35(15_suppl). 9577–9577.

14.

Lattanzi, Michael, Joseph K. Han, Una Moran, et al.. (2016). Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.. Journal of Clinical Oncology. 34(15_suppl). 3084–3084. 2 indexed citations

15.

Lu, Qi, Michael Lattanzi, Yunpeng Chen, et al.. (2011). Supercapacitor Electrodes with High‐Energy and Power Densities Prepared from Monolithic NiO/Ni Nanocomposites. Angewandte Chemie International Edition. 50(30). 6847–6850. 327 indexed citations

16.

Lu, Qi, Michael Lattanzi, Yunpeng Chen, et al.. (2011). Supercapacitor Electrodes with High‐Energy and Power Densities Prepared from Monolithic NiO/Ni Nanocomposites. Angewandte Chemie. 123(30). 6979–6982. 100 indexed citations

17.

Lu, Qi, Michael Lattanzi, Yunpeng Chen, et al.. (2011). Titelbild: Supercapacitor Electrodes with High‐Energy and Power Densities Prepared from Monolithic NiO/Ni Nanocomposites (Angew. Chem. 30/2011). Angewandte Chemie. 123(30). 6803–6803. 7 indexed citations

18.

Lattanzi, Michael, et al.. (2005). Work Goes Mobile: Nokia's Lessons from the Leading Edge. Medical Entomology and Zoology. 2 indexed citations

19.

Fassio, E, et al.. (1992). [Upper digestive hemorrhage in liver cirrhosis: clinical and endoscopic findings].. PubMed. 22(3). 181–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact